A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Telisotuzumab vedotin (Primary) ; Bevacizumab; Carboplatin; Cetuximab; Erlotinib; Nivolumab
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 13 Jul 2018 Planned number of patients changed from 200 to 191.
- 13 Jul 2018 Planned End Date changed from 11 Nov 2019 to 9 Sep 2019.
- 29 May 2018 Planned number of patients changed from 292 to 200.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History